OKYO Pharma Ltd ADR (OKYO)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in OKYO Pharma Ltd ADR, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

OKYO Pharma Ltd ADR (OKYO) has returned -22.22% so far this year and 26.77% over the past 12 months.

Based on dividend-adjusted daily data since May 17, 2022, OKYO's average daily return is +0.13%, while the average monthly return is +0.14%. At this rate, your investment would double in approximately 41.3 years.

Historically, 47% of months were positive and 53% were negative. The best month was Jul 2023 with a return of +63.3%, while the worst month was May 2022 at -43.4%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 3 months.

On a daily basis, OKYO closed higher 45% of trading days. The best single day was Feb 17, 2023 with a return of +63.0%, while the worst single day was Jan 13, 2023 at -27.1%.

OKYO Pharma Ltd ADR has an annualized alpha of 29.68%, beta of 0.55, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since May 18, 2022.

• This stock tended to rise when S&P 500 Index fell (downside capture of -78.61%), but participation in market rallies was also limited (-67.61%) — a profile typical of counter-cyclical assets.
• Beta of 0.55 may look defensive, but with R² of 0.01 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

OKYO ranks 52 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for OKYO Pharma Ltd ADR (OKYO) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the OKYO Pharma Ltd ADR. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the OKYO Pharma Ltd ADR was 74.92%, occurring on Aug 2, 2024. The portfolio has not yet recovered.

The current OKYO Pharma Ltd ADR drawdown is 56.95%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of OKYO Pharma Ltd ADR over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how OKYO Pharma Ltd ADR is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.